BERLIN, Germany, April 17, 2025 / Biotech Newswire / -- ProBioGen recognizes the significance of the commercial availability of Ziihera® (zanidatamab-hrii), a therapeutic antibody developed using ProBioGen's proprietary GlymaxX® technology. In addition, ProBioGen also developed the superior cell line and applied its proprietary media for this antibody. Following FDA approval late last year for the treatment of HER2-positive biliary tract cancer (BTC), this milestone underscores the impact of GlymaxX in advancing innovative biologics and represents a step forward in targeted cancer therapy. A GlymaxX modified cell line can be flexibly used to produce differently fucosylated products, depending on the upstream process: In conjunction with fucose-free medium the antibody is literally afucosylated.
"The market availability of a bispecific therapeutic antibody developed with the GlymaxX technology represents an important milestone," said Dr. Gabriele Schneider, Chief Business Officer at ProBioGen. "It is rewarding to see our technology play a role in therapies that can make a real difference for patients. We are proud to have contributed to Ziihera's journey by providing our cell line, media, and our proprietary technology to help bring this innovative treatment to market. We look forward to continuing to support groundbreaking advancements in biopharmaceuticals."
As precision medicine continues to evolve, ProBioGen remains dedicated to supporting biopharma innovators through cutting-edge technologies and tailored services that drive therapeutic success - with further GlymaxX-enabled achievements expected in the near future.
